Literature DB >> 15152701

The family impact and costs of migraine.

Paul E Stang1, William H Crown, Rich Bizier, Mary Lou Chatterton, Richard White.   

Abstract

OBJECTIVE: To obtain information on migraine and its impact on the family, particularly on the healthcare utilization and productivity of family members without migraine. STUDY
DESIGN: Retrospective study using linked medical and pharmacy claims data that allowed identification of families and individuals with migraine. PATIENTS AND METHODS: Families with at least 1 migraineur were matched with up to 3 nonmigraineur families on employer, age of migraineur, number of family members, sex, and index date quarter. For a subset of employees, data on short- and long-term disability as well as absenteeism also were evaluated to determine the impact of migraine on these indirect costs.
RESULTS: The total healthcare costs of a family with a migraineur were 70% higher than those of the nonmigraine family, with most of the difference concentrated in outpatient costs. The impact of having a migraineur in the family persisted even after controlling for other disorders and demographics in a multivariate model. Total healthcare costs per family depended on which family member was the migraineur, and were about dollars 600 higher when the sole migraineur was a child versus a parent and almost dollars 2500 higher when both a parent and child were affected (compared with families in which the sole migraineur was a child). Work absence days, short-term disability, and workman's compensation days all were higher among migraine families than among families without a migraineur.
CONCLUSION: Migraine families incur far higher direct and indirect healthcare costs than nonmigraine families, with variation depending on which family member is the clinically detected migraineur.

Entities:  

Mesh:

Year:  2004        PMID: 15152701

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

1.  Beyond pain control: Outcome and treatment preferences in pediatric migraine.

Authors:  Matthew J Khayata; Samantha Farley; J Kelly Davis; Christoph P Hornik; Bryce B Reeve; Aruna Rikhi; Amy A Gelfand; Christina L Szperka; Shirley Kessel; Tara Pezzuto; Alex Hammett; Monica E Lemmon
Journal:  Headache       Date:  2022-05-06       Impact factor: 5.311

2.  Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.

Authors:  Andrew D Hershey; Scott W Powers; Christopher S Coffey; Dixie D Eklund; Leigh Ann Chamberlin; Leslie L Korbee
Journal:  Headache       Date:  2013-04-17       Impact factor: 5.887

3.  Impact of bipolar disorder on the family: utilization and cost of health care resources.

Authors:  Mary Lou Chatterton; Xiongkan Ke; Barbara Edelman Lewis; Krithika Rajagopalan; Arthur Lazarus
Journal:  P T       Date:  2008-01

4.  Topiramate: the evidence for its therapeutic value in the prevention of migraine.

Authors:  Carole Nadin
Journal:  Core Evid       Date:  2005-06-30

5.  Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.

Authors:  L C Newman; R K Cady; S Landy; P O'Carroll; W J Kwong; S P Burch; A C Nelsen; S A McDonald
Journal:  Int J Clin Pract       Date:  2008-12       Impact factor: 2.503

6.  Migraine and sleep disorders: a systematic review.

Authors:  Cindy Tiseo; Alessandro Vacca; Anton Felbush; Tamara Filimonova; Annalisa Gai; Tatyana Glazyrina; Irina Anna Hubalek; Yelena Marchenko; Lucas Hendrik Overeem; Serena Piroso; Alexander Tkachev; Paolo Martelletti; Simona Sacco
Journal:  J Headache Pain       Date:  2020-10-27       Impact factor: 7.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.